Voyager Therapeutics Statistics
Share Statistics
Voyager Therapeutics has 55.34M
shares outstanding. The number of shares has increased by 1.5%
in one year.
| Shares Outstanding | 55.34M |
| Shares Change (YoY) | 1.5% |
| Shares Change (QoQ) | 1.06% |
| Owned by Institutions (%) | 59.65% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,315 |
| FTD / Avg. Volume | 2.04% |
Short Selling Information
The latest short interest is 2.9M, so 5.23% of the outstanding
shares have been sold short.
| Short Interest | 2.9M |
| Short % of Shares Out | 5.23% |
| Short % of Float | 6.25% |
| Short Ratio (days to cover) | 11.57 |
Valuation Ratios
The PE ratio is -5.03 and the forward
PE ratio is -2.06.
Voyager Therapeutics's PEG ratio is
0.04.
| PE Ratio | -5.03 |
| Forward PE | -2.06 |
| PS Ratio | 4.09 |
| Forward PS | 2.3 |
| PB Ratio | 1.09 |
| P/FCF Ratio | -17.36 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Voyager Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.56,
with a Debt / Equity ratio of 0.15.
| Current Ratio | 5.56 |
| Quick Ratio | 5.56 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.53 |
| Debt / FCF | -2.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $465,122.09 |
| Profits Per Employee | $-377,918.6 |
| Employee Count | 172 |
| Asset Turnover | 0.2 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 665K |
| Effective Tax Rate | -1.03% |
Stock Price Statistics
The stock price has increased by -61.81% in the
last 52 weeks. The beta is 0.95, so Voyager Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -61.81% |
| 50-Day Moving Average | 3.45 |
| 200-Day Moving Average | 5.36 |
| Relative Strength Index (RSI) | 42.06 |
| Average Volume (20 Days) | 359,078 |
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 80M
and earned -65M
in profits. Earnings per share was -1.13.
| Revenue | 80M |
| Gross Profit | 75.27M |
| Operating Income | -83.29M |
| Net Income | -65M |
| EBITDA | -83.29M |
| EBIT | -83.29M |
| Earnings Per Share (EPS) | -1.13 |
Full Income StatementBalance Sheet
The company has 71.37M in cash and 43.73M in
debt, giving a net cash position of 27.64M.
| Cash & Cash Equivalents | 71.37M |
| Total Debt | 43.73M |
| Net Cash | 27.64M |
| Retained Earnings | -326.18M |
| Total Assets | 353.24M |
| Working Capital | 204.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -15.31M
and capital expenditures -3.52M, giving a free cash flow of -18.83M.
| Operating Cash Flow | -15.31M |
| Capital Expenditures | -3.52M |
| Free Cash Flow | -18.83M |
| FCF Per Share | -0.33 |
Full Cash Flow StatementMargins
Gross margin is 94.09%, with operating and profit margins of -104.11% and -81.25%.
| Gross Margin | 94.09% |
| Operating Margin | -104.11% |
| Pretax Margin | -80.42% |
| Profit Margin | -81.25% |
| EBITDA Margin | -104.11% |
| EBIT Margin | -104.11% |
| FCF Margin | -23.54% |
